心房颤动治疗:现状和未来

doi:10.3969/j.issn.1004-583X.2016.01.002

临床荟萃 ›› 2016, Vol. 31 ›› Issue (1): 7-9.doi: 10.3969/j.issn.1004-583X.2016.01.002

心房颤动治疗:现状和未来

郭雪原, 马长生

首都医科大学附属北京安贞医院心内科,北京 100029

收稿日期:2015-12-23 出版日期:2016-01-05 发布日期:2016-04-19
通讯作者: 马长生,Email: chshma@vip.sina.com
作者简介:马长生,男,1963年11月生。现任首都医科大学附属北京安贞医院心脏内科中心主任。国家心血管病临床医学研究中心主任、北京市心血管疾病防治办公室主任、首都医科大学心血管病学系主任;兼任中国医师协会心内科医师分会会长、中华医学会心血管病学分会副主任委员、中国生物医学工程学会常务理事兼心律分会主任委员,担任JCE、Europace、JICE、CMJ等国内外30余种学术期刊的编委。主要从事心血管疾病的防治和临床实效研究,擅长心房颤动及其他复杂心律失常的导管消融,曾协助国内200余家医院开展手术,培养了大批心律失常介入治疗专业人才,开创了我国心房颤动导管消融事业并引领其发展到国际一流水平。发表论文700余篇(其中SCI收录100余篇),3次获得国家科技进步二等奖。主编《介入心脏病学》、《心律失常射频消融图谱》和《心脏病学实践》等著作,在国内有广泛影响。享受政府特殊津贴,为“北京学者”、“卫生部有突出贡献的中青年专家”、“科技北京百名领军人才”、“北京市高层次卫生技术领军人才”,获“吴阶平保罗杨森医学药学奖”并当选“推动北京创造的科技人物”。
基金资助:
科技部国际合作项目“病毒感染致心血管疾病的机制与干预合作研究”(2013DFB30310)

Atrial fibrillation treatment: present state and future directions

Guo Xueyuan, Ma Changsheng

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Received:2015-12-23 Online:2016-01-05 Published:2016-04-19
Contact: Ma Changsheng,Email: chshma@vip.sina.com

摘要/Abstract

摘要： 心房颤动(房颤)是21世纪的心血管流行病,疾病负担日趋严重。华法林作为房颤卒中预防的有效药物,在我国房颤患者中的应用仍然不足。随着新型口服抗凝药和左心耳封堵技术应用的不断增加,房颤抗栓治疗面临着更多选择。导管消融是阵发性房颤治疗的一线选择,而持续房颤的最佳消融策略仍然存在争议。近年来,生活方式干预在房颤预防和治疗中的价值逐步受到重视。未来,房颤治疗将进入一个崭新的时代。

关键词: 心房颤动, 抗凝药, 导管消融术

Abstract: Atrial fibrillation (AF) is an emerging epidemic of cardiovascular disease in the 21st century, and the disease burden is worsening. Warfarin is used for stroke prevention in AF as an effective drug, but its use in patients with AF of our country is still inadequate. With the continuous increase of new oral anticoagulants and left atrial appendage closure technology applications, antithrombotic treatment of AF is facing more choices. Catheter ablation has become the first-line treatment for paroxysmal AF. However,the best strategy for ablation persistent AF is still controversial. In recent years, more and more focuses have been put on life style intervention in the prevention and treatment of AF. The management of AF will expect a new stage in the future.

Key words: atrial fibrillation, anticoagulants, catheter ablation

中图分类号:

R541.75

郭雪原, 马长生. 心房颤动治疗:现状和未来[J]. 临床荟萃, 2016, 31(1): 7-9.

Guo Xueyuan, Ma Changsheng. Atrial fibrillation treatment: present state and future directions[J]. Clinical Focus, 2016, 31(1): 7-9.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.002

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/7

参考文献

[1] Chugh SS, Havmoeller R, Narayanan K,et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014,129(8):837-847.
[2] Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060[J]. Eur Heart J, 2013,34(35):2746-2751.
[3] Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia[J]. Arch Intern Med, 2012,172(9):739-741.
[4] Shroff GR, Solid CA, Herzog CA, et al. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992-2007)[J]. JAMA Intern Med, 2013,173(2):159-160.
[5] 周自强,胡大一. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志,2004,43(7):491-494.
[6] O'Brien EC, Kim S, Hess PL,et al. Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation[J]. JAMA Intern Med, 2015,175(5):848-850.
[7] Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry[J]. Europace, 2014,16(3):308-319.
[8] Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial[J]. JAMA, 2014,312(19):1988-1998.
[9] Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation[J]. N Engl J Med, 2015,372(19):1812-1822.
[10] Dong JZ, Sang CH, Yu RH,et al. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation[J]. Europace, 2015, May 8.[Epub ahead of print]
[11] Marrouche N, Wilber D, Hindricks G,et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study[J]. JAMA, 2014,311(5):498-506.
[12] Abed HS, Wittert GA, Leong DP,et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial[J]. JAMA, 2013,310(19):2050-2060.
[13] Pathak RK, Middeldorp ME, Lau DH,et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study[J]. J Am Coll Cardio,2014,64(21):2222-2231.

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	李雯琳, 张志. 心房颤动患者左心耳形态结构和功能与左心耳血栓及心源性卒中的关系研究进展[J]. 临床荟萃, 2024, 39(2): 168-171.
[3]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[4]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[5]	马静红, 杨倩, 贾永建, 党懿. 心房颤动导管消融围术期不间断新型口服抗凝剂和不间断华法林抗凝导致心脏压塞风险的荟萃分析[J]. 临床荟萃, 2022, 37(9): 773-778.
[6]	张海福, 叶向晴, 陈者旭, 陈施鉴, 杨栋, 张邢炜. 适量运动对心房颤动患者预后的影响:系统综述与Meta分析[J]. 临床荟萃, 2022, 37(6): 485-489.
[7]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.
[8]	李姮, 李永辉, 孙小强, 王琳, 何峰. 窦性心律慢性心力衰竭患者抗凝治疗安全性及有效性系统评价[J]. 临床荟萃, 2022, 37(5): 406-411.
[9]	李卫伟, 李亚男. 左房容积指数用于预测心房颤动患者射频消融后复发的meta分析[J]. 临床荟萃, 2022, 37(11): 965-968.
[10]	安景景, 王小娟, 邓爱云. 预激综合征伴心房颤动射频消融术后心房颤动复发率的meta分析[J]. 临床荟萃, 2022, 37(10): 899-904.
[11]	曹晶晶, 张英杰, 常丽娟. 心房颤动发病机制及相关生物标志物研究进展[J]. 临床荟萃, 2022, 37(10): 946-949.
[12]	赵美丽, 肖立远, 刘林, 康超, 张秋香. NT-proBNP、hs-CRP、LAD与慢性心力衰竭合并心房颤动的相关性[J]. 临床荟萃, 2021, 36(5): 412-415.
[13]	李文哲, 商进春, 李春梅, 李君, 田芬, 崔莉, 陈怿鹏, 张小凡, 邢广群. 枸橼酸钠抗凝连续性肾脏替代治疗救治尿毒症脑出血患者的优势[J]. 临床荟萃, 2021, 36(5): 425-431.
[14]	耿彦平，王立立，谷剑，齐鹏，陈淑霞. 抗凝治疗量表中文版效度及信度分析[J]. 临床荟萃, 2020, 35(9): 788-791.
[15]	马进才，马溶智，马珍珍. 利伐沙班对合并心功能不全的高龄非瓣膜性心房颤动疗效及安全性[J]. 临床荟萃, 2020, 35(5): 413-416.

心房颤动治疗:现状和未来

Atrial fibrillation treatment: present state and future directions

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价